Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
James Webb Space telescope spots 'big red dot' in the ancient universe: A ravenous supermassive black hole named 'BiRD' - 2Flourishing in a Cutthroat Work Market: Vocation Methodologies
- 3Picking Your Next SUV: 4 Brands Offering Execution, Solace, and Wellbeing
- 4Netflix's Eddie Murphy documentary explains 'Saturday Night Live' beef: 'That's why I didn't go back for years'
- 52 ways you can conserve the water used to make your food
- Mysterious bright blue cosmic blasts triggered by black holes shredding stars, scientists say. 'It's definitely not just an exploding star.'
- 5 VIP Voice Exhibitions in Energized Movies
- Beyond the habitable zone: Exoplanet atmospheres are the next clue to finding life on planets orbiting distant stars
- Photos: Hundreds Gather at Bondi Beach After Deadly Attack
- From Specialist to Proficient Picture taker: Individual Triumphs
- Traveling Alone: An Excursion of Self-Disclosure
- The most effective method to Boost Eco-friendliness in Your Volvo XC40
- Ukraine's new defense minister just outlined how dire its troop shortage has become
- A Couple of Reasonable Guitars for 2024
